SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach
Search This Board: 
Last Post: 12/14/2017 11:21:25 AM - Followers: 68 - Board type: Free - Posts Today: 2

NTRPD Security Details
Share Structure


Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017

COMPANY PRESENTATION

http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf

Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million

 

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

Trial details 
NTRP Security Details
 
 
 
 
 
 
SureTrader
Interactive Brokers Advertisement
NTRP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP News: Additional Proxy Soliciting Materials (definitive) (defa14a) 12/04/2017 04:11:29 PM
NTRP News: Quarterly Report (10-q) 11/03/2017 05:18:44 PM
NTRP News: Current Report Filing (8-k) 10/19/2017 04:07:57 PM
NTRP News: Neurotrope Provides Business Update and Reports Second Quarter 2017 Financial Results 08/09/2017 08:30:00 AM
NTRP News: Quarterly Report (10-q) 08/08/2017 05:19:08 PM
PostSubject
#4967  Sticky Note Full 2a trial article. Some incredible and runncoach 05/15/17 05:57:37 PM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#5479   See know reason why not. Haven’t heard anything Wildginger 12/14/17 11:21:25 AM
#5478   Nice early action today. Guessing we have a runncoach 12/14/17 10:41:40 AM
#5477   That's not what our MOA nor our team runncoach 12/11/17 03:49:22 PM
#5476   Is there a "point of no return" with Alzheimer's? XenaLives 12/11/17 02:11:47 PM
#5475   You're right about that. Not many brave runncoach 12/10/17 09:43:25 PM
#5474   I thought the board might find this interesting. F1ash 12/10/17 06:05:05 PM
#5473   Annual meeting Biostudent 12/10/17 09:30:59 AM
#5472   The 10q stated that they would be runncoach 12/07/17 05:01:59 PM
#5471   Runcoach, thanks again - Biostudent 12/06/17 06:11:43 PM
#5470   Finally got some tax loss selling imo. Nice runncoach 12/05/17 11:59:14 AM
#5469   Just dropped like a rock? from $7.20 to $5.50's... bUrRpPPP! 12/05/17 11:21:04 AM
#5468   Neurotrope presenting at the Biotech Showcase in San runncoach 12/02/17 03:46:04 PM
#5467   LOL. I know they were trying to runncoach 11/22/17 05:04:35 PM
#5466   Well that stinks. Large volume was going runncoach 11/21/17 02:57:30 PM
#5465   yes. bzlegendz 11/21/17 11:43:34 AM
#5464   Was there a trade halt at some point? runncoach 11/21/17 11:23:18 AM
#5463   Thanks. Appear something is leaky Maple tree 11/21/17 10:42:01 AM
#5462   Wild action....why? bUrRpPPP! 11/21/17 10:16:02 AM
#5461   Not sure. Meeting with FDA for next trial runncoach 11/21/17 10:09:22 AM
#5460   Whats happening? Maple tree 11/21/17 10:08:09 AM
#5459   Big volume. Nice open runncoach 11/21/17 10:00:59 AM
#5458   Again, this was shown to be wrong a Whatsupp 11/20/17 11:55:36 PM
#5457   Gotcha. Thanks runncoach 11/20/17 09:37:43 PM
#5456   Yes, the reply definitely sounded like someone promoting InTheTrenches 11/20/17 09:36:30 PM
#5455   Reading the Twitter thread it kind of made runncoach 11/20/17 09:12:41 PM
#5454   Your source sounds more likely, unless they are InTheTrenches 11/20/17 09:07:01 PM
#5453   Not sure trenches but dr. Farlow mentioned in runncoach 11/20/17 09:01:22 PM
#5452   I don't think that Bryostatin can be approved XenaLives 11/20/17 08:55:05 PM
#5451   Posted on twitter by Zachary Prensky: InTheTrenches 11/20/17 08:51:21 PM
#5450   Good point. runncoach 11/20/17 08:44:35 PM
#5449   Good to see you here, coach, biostudent! InTheTrenches 11/20/17 08:43:16 PM
#5448   Also noteworthy is they have proven by multiple runncoach 11/20/17 06:47:37 PM
#5447   Runncoach, thanks for finding. Biostudent 11/20/17 06:38:50 PM
#5446   If the drug is approved don't you think runncoach 11/20/17 06:11:50 PM
#5445   " In addition, based upon certain milestones, the XenaLives 11/20/17 06:04:38 PM
#5444   It's in the filings. runncoach 11/20/17 04:50:58 PM
#5443   Any info on royalties and other obilgations with XenaLives 11/20/17 04:38:35 PM
#5442   bryostatin supply update from October runncoach 11/20/17 03:29:08 PM
#5441   http://www.researcherid.com/ProfileView.action?returnCode=ROUTER.Unauthorized&In F1ash 11/17/17 08:33:12 PM
#5440   I’m going to have to read up on Wildginger 11/17/17 07:27:12 PM
#5439   4 times average volume and highest in 10 runncoach 11/17/17 04:39:12 PM
#5438   Nice move on heavy volume. Hoping for long runncoach 11/17/17 10:35:16 AM
#5437   Institutional ownership... runncoach 11/15/17 05:15:26 PM
#5436   I've used Montelukast for years because I have XenaLives 11/10/17 08:44:46 AM
#5435   Apparently an asthma drug they are hoping could runncoach 11/10/17 07:03:43 AM
#5434   SAINT-LAURENT, QUEBEC--(Marketwired - Nov. 9, 2017) - IntelGenx Tasso9 11/09/17 11:30:21 PM
#5433   10q out runncoach 11/03/17 07:18:33 PM
#5432   He wouldn't be listed in the proxy unless Biostudent 11/01/17 11:45:55 AM
#5431   Will be voted in next month runncoach 11/01/17 10:12:40 AM
#5430   Has he accepted yet??? XenaLives 11/01/17 09:55:24 AM
PostSubject